UCB0107 (bepranemab) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 5 | Progressive supranuclear palsy | 1 |
5. Progressive supranuclear palsy
Clinical trials : 89 / Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04658199 (ClinicalTrials.gov) | November 16, 2020 | 1/12/2020 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: UCB0107 (bepranemab) | UCB Biopharma SRL | NULL | Active, not recruiting | 40 Years | N/A | All | 19 | Phase 1 | Belgium;Germany;Spain;United Kingdom |